Organon & Co Ordinary Shares OGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Organon Announces Quarterly Dividend
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Trading Information
- Previous Close Price
- $13.89
- Day Range
- $13.88–13.89
- 52-Week Range
- $5.70–13.89
- Bid/Ask
- $13.88 / $13.89
- Shares Outstanding
- 262.62M
- Market Cap
- $3.65B
- Volume/Avg
- 835,376 / 3M
Key Statistics
- Price/Earnings (Normalized)
- 4.34
- Price/Sales
- 0.61
- Dividend Yield (Trailing)
- 0.58%
- Dividend Yield (Forward)
- 0.58%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 0.58%
Company Profile
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Value
- Total Number of Employees
- 10,000
- Website
- https://www.organon.com
Valuation
Metric | OGN |
|---|---|
Price/Earnings (Normalized) | 4.34 |
Price/Book Value | 3.06 |
Price/Sales | 0.61 |
Price/Cash Flow | 4.32 |
Price/Earnings
OGN
Financial Strength
Metric | OGN |
|---|---|
Quick Ratio | 1.11 |
Current Ratio | 2.02 |
Interest Coverage | 2.13 |
Quick Ratio
OGN
Profitability
Metric | OGN |
|---|---|
Return on Assets (Normalized) | 4.21% |
Return on Equity (Normalized) | 58.37% |
Return on Invested Capital (Normalized) | 9.26% |
Return on Assets
OGN
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|#YhSWVK | LOCK|!> | $1T | |||
| Johnson & Johnson JNJ | LOCK|^<&<nK | LOCK|hC | $675B | |||
| AbbVie Inc ABBV | LOCK|$rF@!c^ | LOCK|d> | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|v!!?Nsl | LOCK|ZB | $389B | |||
| Merck & Co Inc MRK | LOCK|>pC!BsV | LOCK|G%d | $363B | |||
| Novartis AG ADR NVS | LOCK|qmT!P<?b | LOCK|nC | $304B | |||
| AstraZeneca PLC AZN | LOCK|r>n$#z# | LOCK|@px | $288B | |||
| Amgen Inc AMGN | LOCK|mRM@R$z< | LOCK|CyJ | $253B | |||
| Gilead Sciences Inc GILD | LOCK|%?%qGPt | LOCK|r>T | $211B | |||
| Novo Nordisk AS ADR NVO | LOCK|!^^>J< | LOCK|>Z | $180B |
United States